Table 2 Diagnostic procedures and treatment of group 3 PH patients and control patients
From: Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia
Baseline | Follow-up | |||
|---|---|---|---|---|
Group 3 PH (n = 2236) | Controls (n = 2236) | Group 3 PH (n = 2236) | Controls (n = 2236) | |
Diagnostic procedures | ||||
Echocardiography | 1679 (75.1) | 518 (23.2) | 1678 (75.0) | 441 (19.7) |
Stress echocardiography | 313 (14.0) | 176 (7.9) | 212 (9.5) | 150 (6.7) |
Other radiography | 107 (4.8) | 77 (3.4) | 79 (3.5) | 59 (2.6) |
Electrocardiography | 1779 (79.6) | 1264 (56.5) | 1777 (79.5) | 1160 (51.9) |
Computerized tomography | 1001 (44.8) | 693 (31.0) | 1030 (46.1) | 567 (25.4) |
Angiography | 385 (17.2) | 187 (8.4) | 385 (17.2) | 122 (5.5) |
RHC | 144 (6.4) | 15 (0.7) | 135 (6.0) | 6 (0.3) |
MRI | 39 (1.7) | 17(0.8) | 52 (2.3) | 29 (1.3) |
Other exercise testing | 452 (20.2) | 89 (4.0) | 574 (25.7) | 84 (3.8) |
Therapeutic treatment | ||||
Vena cava procedure | 0 | 0 | 19 (0.9) | 2 (0.09) |
Ventilation perfusion | 76 (3.4) | 12 (0.5) | 58 (2.6) | 2 (0.09) |
Oxygen therapy | 1 (0.04) | 1 (0.04) | 3 (0.1) | 2 (0.09) |
Pharmacotherapy | 366 (16.4) | 33 (1.5) | 495 (22.1) | 41 (1.8) |
Oral anticoagulants | 704 (31.5) | 442 (19.8) | 853 (38.2) | 456 (20.4) |
Diuretics | 1273 (56.9) | 714 (31.9) | 1447 (64.7) | 722 (32.3) |
Calcium channel blockers | 800 (35.8) | 624 (27.9) | 853 (38.2) | 621 (27.8) |
Digoxin | 200 (9.0) | 85 (3.8) | 249 (11.1) | 91 (4.1) |
PAH-approved pharmaceuticalsa | 366 (16.4) | 33 (1.5) | 495 (22.1) | 41 (1.8) |
Prostacyclin analogues | 19 (0.9) | 0 | 34 (1.5) | 0 |
ERAs | 182 (8.1) | 0 | 226 (10.1) | 0 |
PDE5 inhibitorsb | 279 (12.5) | 33 (1.5) | 394 (17.6) | 41 (1.8) |